214 related articles for article (PubMed ID: 30677777)
1. Aggressive and Malignant Prolactinomas.
Olarescu NC; Perez-Rivas LG; Gatto F; Cuny T; Tichomirowa MA; Tamagno G; Gahete MD;
Neuroendocrinology; 2019; 109(1):57-69. PubMed ID: 30677777
[TBL] [Abstract][Full Text] [Related]
2. Giant Prolactinomas.
Shimon I
Neuroendocrinology; 2019; 109(1):51-56. PubMed ID: 30404098
[TBL] [Abstract][Full Text] [Related]
3. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
5. β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.
Demarchi G; Valla S; Perrone S; Chimento A; Bonadeo N; Vitale DL; Spinelli FM; Cervio A; Sevlever G; Alaniz L; Berner S; Cristina C
Tumour Biol; 2022; 44(1):85-105. PubMed ID: 35811548
[TBL] [Abstract][Full Text] [Related]
6. Pituitary prolactin-secreting tumor formation: recent developments.
Xu RK; Wu XM; Di AK; Xu JN; Pang CS; Pang SF
Biol Signals Recept; 2000; 9(1):1-20. PubMed ID: 10686432
[TBL] [Abstract][Full Text] [Related]
7. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
[TBL] [Abstract][Full Text] [Related]
8. Dopamine agonist-resistant prolactinomas.
Oh MC; Aghi MK
J Neurosurg; 2011 May; 114(5):1369-79. PubMed ID: 21214334
[TBL] [Abstract][Full Text] [Related]
9. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
10. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
Almalki MH; Aljoaib NN; Alotaibi MJ; Aldabas BS; Wahedi TS; Ahmad MM; Alshahrani F
Hormones (Athens); 2017 Apr; 16(2):139-149. PubMed ID: 28742502
[TBL] [Abstract][Full Text] [Related]
12. [Indications for surgical treatment of prolactin-secreting pituitary adenomas].
Kalinin PL; Astaf'eva LI; Kadashev BA; Ismailov DB
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(5):117-124. PubMed ID: 29076475
[TBL] [Abstract][Full Text] [Related]
13. ras mutations in human prolactinomas and pituitary carcinomas.
Cai WY; Alexander JM; Hedley-Whyte ET; Scheithauer BW; Jameson JL; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1994 Jan; 78(1):89-93. PubMed ID: 8288721
[TBL] [Abstract][Full Text] [Related]
14. Refractory lactotroph adenomas.
Urwyler SA; Karavitaki N
Pituitary; 2023 Jun; 26(3):273-277. PubMed ID: 36928728
[TBL] [Abstract][Full Text] [Related]
15. Giant prolactinomas: the therapeutic approach.
Moraes AB; Silva CM; Vieira Neto L; Gadelha MR
Clin Endocrinol (Oxf); 2013 Oct; 79(4):447-56. PubMed ID: 23662975
[TBL] [Abstract][Full Text] [Related]
16. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation.
Lania AG; Ferrero S; Pivonello R; Mantovani G; Peverelli E; Di Sarno A; Beck-Peccoz P; Spada A; Colao A
J Clin Endocrinol Metab; 2010 Jan; 95(1):13-7. PubMed ID: 19890024
[TBL] [Abstract][Full Text] [Related]
17. Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.
Cooper O; Mamelak A; Bannykh S; Carmichael J; Bonert V; Lim S; Cook-Wiens G; Ben-Shlomo A
Endocrine; 2014 Jun; 46(2):318-27. PubMed ID: 24287797
[TBL] [Abstract][Full Text] [Related]
18. EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.
Cooper O; Bonert VS; Rudnick J; Pressman BD; Lo J; Salvatori R; Yuen KCJ; Fleseriu M; Melmed S
J Clin Endocrinol Metab; 2021 Jan; 106(2):e917-e925. PubMed ID: 33150390
[TBL] [Abstract][Full Text] [Related]
19. Aggressive prolactinomas: how to manage?
Lasolle H; Ilie MD; Raverot G
Pituitary; 2020 Feb; 23(1):70-77. PubMed ID: 31617128
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and Management Challenges in Prolactinomas.
Vroonen L; Daly AF; Beckers A
Neuroendocrinology; 2019; 109(1):20-27. PubMed ID: 30731464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
